Chargement en cours...
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
Adults with relapsed/refractory B-acute lymphoblastic leukemia (ALL) have a complete remission (CR) rate of 20–45% and median overall survival of 3–9 months, depending on the duration of the first remission and number of lines of salvage therapy. Allogeneic hematopoietic stem cell transplantation (a...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872177/ https://ncbi.nlm.nih.gov/pubmed/27247755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716640422 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|